<meta http-equiv="Content-Type" content="text/html; charset=utf-8"><link type="text/css" rel="stylesheet" href="resources/sheet.css" >
<style type="text/css">.ritz .waffle a { color: inherit; }.ritz .waffle .s2{border-bottom:1px SOLID #000000;border-right:3px SOLID #000000;background-color:#ffffff;text-align:center;font-weight:bold;color:#000000;font-family:docs-Roboto,Arial;font-size:12pt;vertical-align:middle;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s7{border-bottom:3px SOLID #000000;border-right:1px SOLID #000000;background-color:#ffffff;text-align:center;color:#000000;font-family:docs-Roboto,Arial;font-size:12pt;vertical-align:middle;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s5{border-bottom:3px SOLID #000000;border-right:3px SOLID #000000;background-color:#ffffff;text-align:left;color:#000000;font-family:docs-Roboto,Arial;font-size:12pt;vertical-align:middle;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s3{border-bottom:1px SOLID #000000;border-right:1px SOLID #000000;background-color:#ffffff;text-align:center;color:#000000;font-family:docs-Roboto,Arial;font-size:12pt;vertical-align:middle;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s1{border-bottom:3px SOLID #000000;border-right:1px SOLID #000000;background-color:#ffffff;text-align:center;font-weight:bold;color:#000000;font-family:docs-Roboto,Arial;font-size:12pt;vertical-align:middle;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s4{border-bottom:1px SOLID #000000;border-right:1px SOLID #000000;background-color:#ffffff;text-align:left;color:#000000;font-family:docs-Roboto,Arial;font-size:12pt;vertical-align:middle;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s0{border-bottom:3px SOLID #000000;border-right:3px SOLID #000000;background-color:#ffffff;text-align:center;font-weight:bold;color:#000000;font-family:docs-Roboto,Arial;font-size:12pt;vertical-align:middle;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s6{border-bottom:3px SOLID #000000;border-right:1px SOLID #000000;background-color:#ffffff;text-align:left;color:#000000;font-family:docs-Roboto,Arial;font-size:12pt;vertical-align:middle;white-space:normal;overflow:hidden;word-wrap:break-word;direction:ltr;padding:2px 3px 2px 3px;}</style><div class="ritz grid-container" dir="ltr"><table class="waffle" cellspacing="0" cellpadding="0"><thead><tr><th class="row-header"></th><th id="0C0" style="width:182px;" class="column-headers-background">A</th><th class="freezebar-cell frozen-column-cell freezebar-vertical-handle"></th><th id="0C1" style="width:158px;" class="column-headers-background">B</th><th id="0C2" style="width:186px;" class="column-headers-background">C</th><th id="0C3" style="width:252px;" class="column-headers-background">D</th><th id="0C4" style="width:564px;" class="column-headers-background">E</th><th id="0C5" style="width:535px;" class="column-headers-background">F</th><th id="0C6" style="width:250px;" class="column-headers-background">G</th><th id="0C7" style="width:254px;" class="column-headers-background">H</th><th id="0C8" style="width:1561px;" class="column-headers-background">I</th></tr></thead><tbody><tr style="height: 20px"><th id="0R0" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">1</div></th><td class="s0" dir="ltr">Dysferlinopathy</td><td class="freezebar-cell"></td><td class="s1" dir="ltr">Age onset</td><td class="s1" dir="ltr">Type</td><td class="s1" dir="ltr">Initial symptoms</td><td class="s1" dir="ltr">Progression</td><td class="s1" dir="ltr">Muscle biopsies</td><td class="s1" dir="ltr">Caridac involvement</td><td class="s1" dir="ltr">Respiratory involvement</td><td class="s0" dir="ltr">References</td></tr><tr><th style="height:3px;" class="freezebar-cell freezebar-horizontal-handle"></th><td class="freezebar-cell"></td><td class="freezebar-cell"></td><td class="freezebar-cell"></td><td class="freezebar-cell"></td><td class="freezebar-cell"></td><td class="freezebar-cell"></td><td class="freezebar-cell"></td><td class="freezebar-cell"></td><td class="freezebar-cell"></td><td class="freezebar-cell"></td></tr><tr style="height: 20px"><th id="0R1" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">2</div></th><td class="s2" dir="ltr">General symptoms</td><td class="freezebar-cell"></td><td class="s3" dir="ltr">~ 20</td><td class="s3" dir="ltr">NA</td><td class="s4" dir="ltr" colspan="2">→ Their symptoms include muscle wasting (27%); pain, stiffness, or cramps (13%); and pseudohypertrophy (6%). Patients&#39; creatine kinase (CK) levels are, on average, 54 times higher than those of control groups. They typically begin using a cane in their thirties and become wheelchair-bound in their forties or, on average, 21 years after symptom onset. The age at which patients become wheelchair bound ranges from 25 to 54 years (on average 38 years). Among the affected muscles, the gastrocnemius, soleus, and subscapularis are particularly vulnerable in dysferlinopathies, whereas others, such as the levator scapulae, are relatively spared; the underlying cause of this pattern remains unclear. While muscle involvement is generally symmetrical, some patients may exhibit asymmetrical muscle degradation.<br>→ A high proportion of dysferlinopathy patients are physically active before the onset of symptoms (53% of patients)16 and have had good performance in sports or physically demanding jobs. According to the most accepted hypothesis, sarcolemmal lesions due to exercise accumulate during the presymptomatic stage of the disease, where they produce molecular signaling of damage and extensive inflammation, leading to fiber damage and necrosis. In one study muscle functional grade 4 of the Gardner-Medwin Walton scale was reached on average 2 years faster in the sports patients than the nonsports patients. Traumatic events may occasionally precipitate the onset of disease.<br>→ MRI studies reveal increased fat infiltration in muscles, particularly in non-ambulant patients, with the quadriceps often being severely affected. In contrast, the contractile area tends to decrease.<br>→ Dysferlinopathies are frequently misdiagnosed due to symptom overlap with conditions such as polymyositis (PM), other limb-girdle muscular dystrophies (LGMDs), and Charcot–Marie–Tooth disease (CMT).<br>→ The greater degree of complement C5b-9 deposition in DYSF distinguishes it from other dystrophies + lower number of cellular inflammatory infiltrates with a predominance of macrophages and minimal MHC class I expression</td><td class="s4" dir="ltr">→ Variability in muscle fibre sizes <br>→ Presence of necrotic and regenerating fibres <br>→ Fibre splitting observed <br>→ Increased endomysial and perimysial connective tissue<br>→ Presence of amyloid deposits in vessel walls and in the perimysium, corresponding to misfolded dysferlin protein <br>→ Proliferation of connective tissue <br>→ High number of internalised nuclei <br>→ Major histocompatibility complex class I (MHC-I) labelling was colocalized with macrophages and expressed on the sarcolemma of nonnecrotic muscle fibers<br>→ The increased expression of 2 inflammasome components (caspase-1, ASC-1) has led to the suggestion of the following cascade of events consequent to impaired membrane repair: (1) prolonged release of endogenous danger molecules leads to local activation of the complement system and up-regulation of the inflammasome; (2) danger molecules are recognized by receptors on leukocytes and muscle fibers, stimulating the production of proinflammatory cytokines, making the vascular endothelium “leaky,” and attracting migration of leukocytes; (3) this cellular response causes additional damage and necrosis, further release of danger molecules, and muscle inflammation<br>→ Granular membrane attack complex deposits on non-necrotic fibres <br>→ Small membrane defects, especially in hypercontracted or necrotic fibres <br>→ Small vesicles forming layered structures to replace the sarcolemma <br>→ Thickening/duplication of the basal lamina in 35% of patient fibres <br>→ Subsarcolemmal vacuoles and increased rough ER <br>→ the following sequence of pathogenic steps has been suggested: (1) sarcolemmal lesions and gaps, (2) accumulation of vesicles, (3) formation of papillary projections, and (4) multiple stratification of basal lamina, inflammation, and regeneration/degeneration.<br>Findings can vary between patients, with some results based on case studies</td><td class="s4" dir="ltr" colspan="2">The phenotype primarily affects skeletal muscles, while the heart remains largely unaffected, with normal electrocardiogram and echocardiogram results. However, a three-year study found that up to 30% of patients have a reduced forced vital capacity (FVC), and up to 58% exhibit a cardiac P-wave abnormality, which can increase the risk of atrial flutter. A cardiac MRI study showed subclinical myocardial fibrosis in 33% of patients, which was associated in half of cases with diastolic dysfunction. Many patients develop latent cardiac dysfunction, and a few patients have dilated cardiomyopathy, other cardiac rhythm changes, or left ventricular hypertrophy. One patient died with hypertrophic obstructive cardiomyopathy and supraventricular tachycardia requiring pacing. In a 23-year follow-up study to investigate disease progression, many patients developed restrictive lung disease with mild obstructive signs in small airways, reduced forced vital capacity, and severe respiratory failure.</td><td class="s5" dir="ltr" rowspan="6">Anwar, Saeed, and Toshifumi Yokota. ‘The Dysferlinopathies Conundrum: Clinical Spectra, Disease Mechanism and Genetic Approaches for Treatments’. Biomolecules 14, no. 3 (21 February 2024): 256. https://doi.org/10.3390/biom14030256.<br><br>Becker, Nicole, Steven A. Moore, and Karra A. Jones. ‘The Inflammatory Pathology of Dysferlinopathy Is Distinct from Calpainopathy, Becker Muscular Dystrophy, and Inflammatory Myopathies’. Acta Neuropathologica Communications 10, no. 1 (December 2022). https://doi.org/10.1186/s40478-022-01320-z.<br><br>Benn, Kieran W, Oneil G Bhalala, Timothy J Day, and Christopher R French. ‘Diagnosis of Dysferlinopathy Masked by a Superimposed Hypothyroid Myopathy’. BMJ Case Reports 17, no. 8 (August 2024): e260986. https://doi.org/10.1136/bcr-2024-260986.<br><br>Biondi, Olivier, Marie Villemeur, Alice Marchand, Fabrice Chretien, Nathalie Bourg, Romain K. Gherardi, Isabelle Richard, and François-Jérôme Authier. ‘Dual Effects of Exercise in Dysferlinopathy’. The American Journal of Pathology 182, no. 6 (June 2013): 2298–2309. https://doi.org/10.1016/j.ajpath.2013.02.045.<br><br>Bouchard, Camille, and Jacques P. Tremblay. ‘Portrait of Dysferlinopathy: Diagnosis and Development of Therapy’. Journal of Clinical Medicine 12, no. 18 (16 September 2023): 6011. https://doi.org/10.3390/jcm12186011.<br><br>Cacciottolo, Mafalda, Gelsomina Numitone, Stefania Aurino, Imma Rosaria Caserta, Marina Fanin, Luisa Politano, Carlo Minetti, et al. ‘Muscular Dystrophy with Marked Dysferlin Deficiency Is Consistently Caused by Primary Dysferlin Gene Mutations’. European Journal of Human Genetics: EJHG 19, no. 9 (September 2011): 974–80. https://doi.org/10.1038/ejhg.2011.70.<br><br>Chiu, Yen-Hui, Mark A. Hornsey, Lars Klinge, Louise H. Jørgensen, Steven H. Laval, Richard Charlton, Rita Barresi, Volker Straub, Hanns Lochmüller, and Kate Bushby. ‘Attenuated Muscle Regeneration Is a Key Factor in Dysferlin-Deficient Muscular Dystrophy’. Human Molecular Genetics 18, no. 11 (1 June 2009): 1976–89. https://doi.org/10.1093/hmg/ddp121.<br><br>Diaz-Manera, Jordi, Roberto Fernandez-Torron, Jaume LLauger, Meredith K James, Anna Mayhew, Fiona E Smith, Ursula R Moore, et al. ‘Muscle MRI in Patients with Dysferlinopathy: Pattern Recognition and Implications for Clinical Trials’. Journal of Neurology, Neurosurgery &amp; Psychiatry 89, no. 10 (October 2018): 1071–81. https://doi.org/10.1136/jnnp-2017-317488.<br><br>Donen, Graham S., Zoe White, Elodie Sauge, Morten Ritso, Marine Theret, John Boyd, Angela M. Devlin, Fabio M. V. Rossi, and Pascal Bernatchez. ‘Thermoneutral Housing and a Western Diet Combination Exacerbates Dysferlin‐Deficient Muscular Dystrophy’. Muscle &amp; Nerve 66, no. 4 (October 2022): 513–22. https://doi.org/10.1002/mus.27680.<br><br>Fanin, Marina, and C. Angelini. ‘Muscle Pathology in Dysferlin Deficiency’. Neuropathology and Applied Neurobiology 28, no. 6 (2002): 461–70.<br><br>Fanin, Marina, and Corrado Angelini. ‘Progress and Challenges in Diagnosis of Dysferlinopathy: Dysferlinopathy Diagnosis’. Muscle &amp; Nerve 54, no. 5 (November 2016): 821–35. https://doi.org/10.1002/mus.25367.<br><br>Hnilicova, Petra, Marian Grendar, Monika Turcanova Koprusakova, Alzbeta Trancikova Kralova, Jana Harsanyiova, Martin Krssak, Ivica Just, et al. ‘Brain of Miyoshi Myopathy/Dysferlinopathy Patients Presents with Structural and Metabolic Anomalies’. Scientific Reports 14, no. 1 (20 August 2024). https://doi.org/10.1038/s41598-024-69966-4.<br><br>Jacobs, Marni B., Meredith K. James, Linda P. Lowes, Lindsay N. Alfano, Michelle Eagle, Robert Muni Lofra, Ursula Moore, et al. ‘Assessing Dysferlinopathy Patients Over Three Years With a New Motor Scale’. Annals of Neurology 89, no. 5 (May 2021): 967–78. https://doi.org/10.1002/ana.26044.<br><br>Lloyd, Erin M., Matt S. Hepburn, Jiayue Li, Alireza Mowla, Ji Hoon Jeong, Yongsung Hwang, Yu Suk Choi, Connie Jackaman, Brendan F. Kennedy, and Miranda D. Grounds. ‘Multimodal Three-Dimensional Characterization of Murine Skeletal Muscle Micro-Scale Elasticity, Structure, and Composition: Impact of Dysferlinopathy, Duchenne Muscular Dystrophy, and Age on Three Hind-Limb Muscles’. Journal of the Mechanical Behavior of Biomedical Materials 160 (December 2024): 106751. https://doi.org/10.1016/j.jmbbm.2024.106751.<br><br>Ng, Rainer, Glen B. Banks, John K. Hall, Lindsey A. Muir, Julian N. Ramos, Jacqueline Wicki, Guy L. Odom, Patryk Konieczny, Jane Seto, and Joel R. Chamberlain. ‘Animal Models of Muscular Dystrophy’. Progress in Molecular Biology and Translational Science 105 (2012): 83–111.<br><br>Nishimura, Anna, Christopher Nelke, Melanie Huber, Alexander Mensch, Angela Roth, Christoph Oberwittler, Björn Zimmerlein, et al. ‘Differentiating Idiopathic Inflammatory Myopathies by Automated Morphometric Analysis of MHC‐1, MHC‐2 and ICAM‐1 in Muscle Tissue’. Neuropathology and Applied Neurobiology 50, no. 4 (August 2024). https://doi.org/10.1111/nan.12998.<br><br>Poudel, Bal Hari, Sue Fletcher, Steve D. Wilton, and May Aung-Htut. ‘Limb Girdle Muscular Dystrophy Type 2B (LGMD2B): Diagnosis and Therapeutic Possibilities’. International Journal of Molecular Sciences 25, no. 11 (21 May 2024): 5572. https://doi.org/10.3390/ijms25115572.<br><br>Roche, Joseph A., Richard M. Lovering, Renuka Roche, Lisa W. Ru, Patrick W. Reed, and Robert J. Bloch. ‘Extensive Mononuclear Infiltration and Myogenesis Characterize Recovery of Dysferlin-Null Skeletal Muscle from Contraction-Induced Injuries’. American Journal of Physiology-Cell Physiology 298, no. 2 (2010): C298–312.<br><br>Zhang, Huili, Yaqin Li, Qiusheng Cheng, Xi Chen, Qiuxia Yu, and Ze Li. ‘Abnormal Expression of Dysferlin in Blood Monocytes Supports Primary Dysferlinopathy in Patients Confirmed by Genetic Analyses’. Frontiers in Neurology 11 (4 February 2021). https://doi.org/10.3389/fneur.2020.540098.</td></tr><tr style="height: 20px"><th id="0R2" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">3</div></th><td class="s2" dir="ltr">LGMDR2<br>(Most frequent)</td><td class="freezebar-cell"></td><td class="s3" dir="ltr">Between 13 and 40 Mean 21+/-7</td><td class="s3" dir="ltr">Proximal</td><td class="s4" dir="ltr">Weakness and atrophy of the proximal muscles, especially the gluteus maximus (buttock) and quadriceps (thigh) muscles</td><td class="s4" dir="ltr">The disease progresses slowly, initially affecting proximal muscles before spreading to distal muscles, typically in a symmetrical pattern. Patients commonly experience fatigue, difficulty climbing stairs, and general muscle weakness. In advanced stages, 15–50% of patients may lose ambulation entirely and become wheelchair-bound.</td><td class="s4" dir="ltr" rowspan="4">→ No/very low levels of dysferlin in muscle fibers<br>→ Muscle damage with degeneration / regeneration of the muscle fibers: Varied fiber sizes and the presence of necrotic and regenerating fibers and possible membrane damage (subsarcolemmal vesicles and vacuoles).<br>→ Inflammation with cells that invade the muscle tissue<br>→ Scar tissue (from necrosis) and fat deposits that replace muscle tissue<br>These changes can vary in severity and distribution among different types of dysferlinopathy</td><td class="s6" dir="ltr" rowspan="5">Rare, 3–10% patients may develop cardiac dysfunction or arrhythmias; may require cardiac monitoring and treatment if present</td><td class="s6" dir="ltr" rowspan="5">Uncommon, 20–30% patients may develop respiratory impairment and/or sleep apnea; may require respiratory monitoring and treatment if present</td></tr><tr style="height: 20px"><th id="0R3" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">4</div></th><td class="s2" dir="ltr">Miyoshy myopathy<br>(Most frequent)</td><td class="freezebar-cell"></td><td class="s3" dir="ltr">Between 14 and 40 Mean 20+/-5</td><td class="s3" dir="ltr">Distal</td><td class="s4" dir="ltr">Weakness and atrophy of the distal muscles, especially the gastrocnemius (calf) and soleus (lower leg) muscles</td><td class="s4" dir="ltr">Slowly progressive (may be faster than LGMDR2), spreading to other distal muscles and eventually affecting proximal muscles; usually symmetrical. Patients experience difficulties with walking and stair climbing. A distinguishing feature of MM is calf discomfort and pain, which sets it apart from other distal muscular dystrophies.</td></tr><tr style="height: 20px"><th id="0R4" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">5</div></th><td class="s2" dir="ltr">DMAT<br>(Rarest of the 3 major type)</td><td class="freezebar-cell"></td><td class="s3" dir="ltr">Between 14 and 30</td><td class="s3" dir="ltr">Distal (anterior tibial)</td><td class="s4" dir="ltr">Weakness and atrophy of the distal muscles, especially the anterior tibialis (shin) and extensor digitorum longus (toe extensor) muscles</td><td class="s4" dir="ltr">Slowly progressive (may be faster than LGMDR2 and MM), spreading to other distal muscles and sometimes affecting proximal muscles; usually symmetrical. Leg weakness, specifically in the anterior compartment of the leg, leading to foot drop. It progresses faster than LGMDR2 and MM</td></tr><tr style="height: 20px"><th id="0R5" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">6</div></th><td class="s2" dir="ltr">Dysferlin-Deficient Proximo-Distal Phenotype</td><td class="freezebar-cell"></td><td class="s3" dir="ltr">Early 20 to 30</td><td class="s3" dir="ltr">Proximal and distal combined</td><td class="s4" dir="ltr">Weakness and atrophy of both proximal and distal muscles, with variable distribution and severity</td><td class="s4" dir="ltr">Slowly (variable compared to LGMDR2, MM, and DMAT) progressive, affecting both proximal and distal muscles in a symmetrical or asymmetrical pattern; may have focal or regional involvement</td></tr><tr style="height: 20px"><th id="0R6" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">7</div></th><td class="s0" dir="ltr">Asymptomatic HyperCKemia</td><td class="freezebar-cell"></td><td class="s7" dir="ltr">NA</td><td class="s7" dir="ltr">NA</td><td class="s6" dir="ltr">Only elevated serum CK levels with no or insignificant muscle weakness or other symptoms</td><td class="s6" dir="ltr">Stable or fluctuating CK levels with no or insignificant muscle involvement</td><td class="s6" dir="ltr">→ No/low levels of dysferlin in muscle fibers<br>→ Mild or no changes in muscle fibers<br>→ No inflammation, scar tissue, or fat deposits</td></tr></tbody></table></div>
